Latest news
Darlifarnib Plus Cabozantinib Yields ORRs Up to 50% in Cabozantinib-Naive ccRCC - OncLiveOncLive · Mon, 03 Aug 2026 12:07:09 GMTKura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib in Renal Cell Carcinoma - Slideshow (NASDAQ:KURA) 2026-07-29 - Seeking AlphaSeeking Alpha · Wed, 29 Jul 2026 07:00:00 GMTAdanma Ayanambakkam, MD, discusses phase 1 data on darlifarnib plus cabozantinib in RCC - Urology TimesUrology Times · Tue, 28 Jul 2026 07:00:00 GMTAnalyst Maintains Buy Rating and Unchanged $40 Price Target on Encouraging Darlifarnib Combination Data in Advanced RCC - TipRanksTipRanks · Mon, 27 Jul 2026 18:51:46 GMTCharles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data - TipRanksTipRanks · Mon, 27 Jul 2026 18:51:46 GMTDarlifarnib Plus Cabozantinib Shows Durable Activity in Advanced RCC - Targeted OncologyTargeted Oncology · Mon, 27 Jul 2026 15:10:16 GMTKURA: Darlifarnib plus cabozantinib showed durable responses and manageable safety in advanced RCC - TradingViewTradingView · Mon, 27 Jul 2026 13:06:27 GMTKura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 - markets.businessinsider.commarkets.businessinsider.com · Mon, 27 Jul 2026 07:00:00 GMT